# US 2022/0010383 A1 · Use of disulfiram and other compounds to treat cancers with loss of chromosome 16q and/or low expression of metallothionein proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010383 A1
- Document ID: US20220010383A1
- Status: Published application
- Kind: A1
- Application number: 17/293,381
- Filed: 2019-11-13
- Published: 2022-01-13
- Earliest claimed: 2018-11-14
- Assignees: The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.; Instituto Carlos Slim De La Salud, A.C.
- Applicants: The Broad Institute, Inc.; Dana-Farber Cancer Institute, Inc.; Instituto Carlos Slim De La Salud, A.C.
- Inventors: Steven CORSELLO; Ryan SPANGLER; Rohith NAGARI; Todd GOLUB
- Web page: https://patentgrep.com/patent/US20220010383A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- G01N 33/5752: of the lungs
- G01N 33/57545: of the ovaries
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothionein proteins, such as certain uterine, ovarian, gastroesophageal and lung cancers. Three known drugs, disulfiram, elesclomol and thiram, as well as certain disulfiram metabolites, are specifically provided for killing cancer cells characterized by arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothioneins. The instant disclosure therefore provides for selecting and/or administering disulfiram, elesclomol and thiram and/or active metabolites or derivatives of disulfiram, elesclomol and thiram as a therapeutic agent(s) to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.

## Claims

### Claim 1

A method for selecting a treatment for a subject having or at risk of developing a cancer, the method comprising:
(a) obtaining a sample from a subject having or at risk of developing a cancer;
(b) identifying the presence or absence in the sample of one or more of the following: arm-level loss of 16q, focal copy loss of 16q13, and low expression of a metallothionein gene and/or protein; and
(c) selecting disulfiram, a metabolite or derivative of disulfiram, elesclomol, a derivative of elesclomol, thiram and/or a derivative of thiram as a treatment for the subject if arm-level loss of 16q, focal copy loss of 16q13 and/or low expression of a metallothionein gene and/or protein is identified in the sample,
thereby selecting a treatment for the subject having or at risk of developing a cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, optionally wherein the lung cancer is non-small cell lung cancer (NSCLC).

### Claim 3 (depends on 1)

The method of claim 1, wherein the metallothionein gene and/or protein is a MT1 isoform, optionally MT1E.

### Claim 4 (depends on 1)

The method of claim 1, wherein the metallothionein gene and/or protein is a MT2 isoform, optionally MT2A.

### Claim 5 (depends on 1)

The method of claim 1, wherein low expression of MT1E or MT2A mRNA is identified.

### Claim 6 (depends on 1)

The method of claim 1, wherein methylation of the metallothionein gene is identified, optionally wherein methylation of a MT1E gene and/or MT2A gene is identified.

### Claim 7 (depends on 1)

The method of claim 1, wherein step (b) comprises identifying the presence or absence in the sample of reduced MT1E or MT2A mRNA expression, as compared to an appropriate control.

### Claim 8 (depends on 1)

The method of claim 1, wherein the metabolite or derivative of disulfiram is DDC or Cu-DDC.

### Claim 9 (depends on 1)

The method of claim 1, further comprising: (d) administering the selected disulfiram, metabolite or derivative of disulfiram, elesclomol, derivative of elesclomol, thiram and/or derivative of thiram to the subject.

### Claim 10 (depends on 1)

The method of claim 1, further comprising selection of vinorelbine, a platinum agent, Letrozole, Anastrozole, Exemestane, Doxorubicin, Liposomal doxorubicin, Cyclophosphamide, Capecitabine, Docetaxel, Paclitaxel, Nab-paclitaxel, Trastuzumab, Ado-trastuzumab emtansine, Pertuzumab, Neratinib, Gemcitabine, Tamoxifen, Methotrexate, 5-Fluorouracil, Palbociclib, Abemaciclib, Fulvestrant, Olaparib, Eribulin, Pemetrexed, bevacizumab, nivolumab, pembrolizumab, ipilimumab, Oxaliplatin and/or ramucirumab as a combination therapy for the subject with the selected disulfiram, metabolite or derivative of disulfiram, elesclomol, derivative of elesclomol, thiram and/or derivative of thiram, optionally wherein the platinum agent is cisplatin or carboplatin.

### Claim 11 (depends on 1)

The method of claim 1, wherein identifying step (b) comprises use of a kit for identifying low expression of a metallothionein mRNA or protein in a sample consisting essentially of an oligonucleotide for detection of a metallothionein mRNA or an anti-metallothionein antibody (optionally labeled or wherein the kit comprises a labeled secondary antibody that binds the anti-metallothionein antibody).

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 13

A method for treating or preventing a cancer in a subject, the method comprising:
(a) obtaining a sample from a subject having or at risk of developing a cancer;
(b) identifying the presence or absence in the sample of one or more of the following: arm-level loss of 16q, focal copy loss of 16q13, and low expression of a metallothionein gene and/or protein; and
(c) administering disulfiram, a metabolite or derivative of disulfiram, elesclomol, a derivative of elesclomol, thiram and/or a derivative of thiram to the subject if arm-level loss of 16q, focal copy loss of 16q13 and/or low expression of a metallothionein gene and/or protein is identified in the sample,
thereby treating or preventing a cancer in the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, optionally wherein the lung cancer is a NSCLC.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer possesses one or more of the following: low MT1E mRNA expression levels, low MT1E protein expression levels, low MT2A mRNA expression levels and/or low MT2A protein expression levels.

### Claim 16

A composition selected from the group consisting of:
A kit for identifying low expression of a metallothionein mRNA or protein in a sample consisting essentially of an oligonucleotide for detection of a metallothionein mRNA or an anti-metallothionein antibody (optionally labeled or wherein the kit comprises a labeled secondary antibody that binds the anti-metallothionein antibody), and instructions for its use; and
A pharmaceutical composition for treating a subject having a cancer having arm-level loss of 16q, focal copy loss of 16q13 and/or low expression of a metallothionein gene and/or protein, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, the pharmaceutical composition comprising a therapeutically effective amount of disulfiram, a metabolite or derivative of disulfiram, elesclomol, a derivative of elesclomol, thiram and/or a derivative of thiram and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the sample is a cancer sample, optionally wherein the cancer sample is selected from the group consisting of a uterine cancer sample, an ovarian cancer sample, a gastroesophageal cancer sample and a lung cancer sample, optionally wherein the cancer sample is a NSCLC sample.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the sample is a tissue sample of a subject having a cancer selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, optionally wherein the lung cancer is a NSCLC.

### Claim 19 (depends on 16)

The composition of claim 16, wherein the metallothionein mRNA or protein is a MT1E mRNA or protein or a MT2A mRNA or protein.

### Claim 20

(canceled)

### Claim 21 (depends on 16)

The composition of claim 16, wherein:
the cancer is a NSCLC;
the subject is human; and/or
the metabolite or derivative of disulfiram is DDC or Cu-DDC.

### Claim at position 22

22-23. (canceled)
